ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at BTIG's Virtual Biotechnology Conference 2021
To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease (VAR 200), please request a one-on-one meeting.
- To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease (VAR 200), please request a one-on-one meeting.
- ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs.
- Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs.
- View original content to download multimedia: https://www.prnewswire.com/news-releases/zyversa-therapeutics-ceo-stephe...